Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Modulation + Ultrasound BBB Opening in Newly Diagnosed Glioblastoma
NCT05864534Phase 2Active, not recruiting
- Sponsor
- Northwestern University
- Start
- Jan 2024
- Primary completion
- Jul 2031
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of balstilimab, botensilimab, pegylated liposomal doxorubicin in glioblastoma (GBM), sponsored by Northwestern University. Started Jan 2024; status: active, not recruiting.
02
Drugs
balstilimabbotensilimabpegylated liposomal doxorubicin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05864534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05864534.